Published in Intensive Care Med on December 01, 1996
Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care (2006) 1.76
Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care (2005) 1.65
Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection (2006) 1.40
Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care (2015) 1.28
Aspergillosis in the ICU: the glass half-empty? Intensive Care Med (1996) 0.75
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med (1996) 35.00
Increased plasma levels of interleukin-6 in sepsis. Blood (1989) 3.92
Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet (1998) 2.84
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med (1999) 2.33
Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med (1998) 2.12
A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods (1994) 2.06
Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol (1995) 2.04
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 2.01
Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun (1992) 1.85
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis (2007) 1.79
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol (1994) 1.75
Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med (1992) 1.65
Transvascular transport of 67Ga in the lungs after cardiopulmonary bypass surgery. Chest (1993) 1.64
C1-esterase inhibitor substitution in sepsis. Lancet (1992) 1.61
Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest (1998) 1.61
Role of cytokines in sepsis. Adv Immunol (1997) 1.60
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol (1999) 1.60
Continuous cardiac output in septic shock by simulating a model of the aortic input impedance: a comparison with bolus injection thermodilution. Anesthesiology (1999) 1.57
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med (2000) 1.52
Nasal T-cell lymphoma: a clinicopathological and immunophenotypic analysis of 13 cases. Histopathology (1995) 1.51
Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med (2000) 1.49
Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med (1992) 1.48
Cardiac tamponade from misplaced central venous line in pericardiophrenic vein. Arch Intern Med (1988) 1.48
Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood (1995) 1.47
Deep vein thrombosis as a presenting symptom of congenital interruption of the inferior vena cava. Int J Clin Pract (1999) 1.46
Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol (2006) 1.46
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med (1990) 1.43
Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron (1991) 1.41
Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. Int J Oral Maxillofac Surg (2005) 1.41
[Hyperthyroidism induced by iodinated roentgen contrast media]. Ned Tijdschr Geneeskd (1998) 1.40
[Increased frequency of icterus in parenterally fed patients after a change of lipid emulsion]. Ned Tijdschr Geneeskd (1999) 1.40
[The HITT syndrome: heparin-induced thrombocytopenia and thrombosis as a cause of paradoxically occurring thromboembolisms]. Ned Tijdschr Geneeskd (1994) 1.39
[Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]. Ned Tijdschr Geneeskd (2000) 1.39
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd (2005) 1.38
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med (1989) 1.34
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol (1990) 1.34
Primary extranodal non-Hodgkin lymphoma of the oral cavity. An analysis of 34 cases. Eur J Cancer B Oral Oncol (1994) 1.31
Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun (2000) 1.30
Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables. Clin Infect Dis (1999) 1.26
Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med (2001) 1.26
BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood (1995) 1.24
Immunohistochemistry in bone marrow diagnosis. Value of a panel of monoclonal antibodies on routinely processed bone marrow biopsies. Am J Surg Pathol (1989) 1.24
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia (2004) 1.23
Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest (1989) 1.22
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol (1998) 1.21
Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med (1988) 1.20
Interobserver variability in the use of APACHE II scores. Lancet (1999) 1.19
Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab (2001) 1.18
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg (2001) 1.16
Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood (1988) 1.15
Hypophyseal non-Hodgkin's lymphoma presenting with clinical panhypopituitarism successfully treated with chemotherapy. J Neurooncol (1993) 1.13
Accuracy and reliability of APACHE II scoring in two intensive care units Problems and pitfalls in the use of APACHE II and suggestions for improvement. Anaesthesia (2001) 1.10
[Corticosteroid administration for critically ill patients]. Ned Tijdschr Geneeskd (2001) 1.07
New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. Neth J Med (2011) 1.07
Hemodynamic determinants of mortality in human septic shock. Surgery (1986) 1.07
Frequencies of lipopolysaccharide core types in Escherichia coli strains from bacteraemic patients. Microbiology (1994) 1.06
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood (1996) 1.06
Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. J Immunol Methods (1991) 1.06
Plasma lipid peroxides and antioxidants in human septic shock. Intensive Care Med (1991) 1.04
Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies. Bone Marrow Transplant (2011) 1.04
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide study. Am Heart J (1988) 1.04
Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost (1998) 1.03
Methylene blue increases myocardial function in septic shock. Crit Care Med (1995) 1.03
ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology (2003) 1.03
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood (1999) 1.03
International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med (1996) 1.02
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia (1997) 1.01
Relative adrenal failure in intensive care: an identifiable problem requiring treatment? Best Pract Res Clin Endocrinol Metab (2001) 1.01
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia (2004) 1.01
Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli. J Med Microbiol (1988) 1.00
Long-term effects of vincristine on the peripheral nervous system. J Neurooncol (1993) 1.00
Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol (2005) 1.00
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia (2011) 1.00
Arginase release from red blood cells: possible link in transfusion induced immune suppression? Shock (2001) 0.99
alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med (2001) 0.99
Comment on 'psychological distress in patients with cancer: is screening the effective solution?'. Br J Cancer (2013) 0.98
Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis (1998) 0.98
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology (2005) 0.98
Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (1996) 0.97